SecBot SecBot
EFFECT ·Filed Aug 26, 2026

INDP

Indaptus Therapeutics, Inc.
BEARISH
Impact 7/10
Horizondays Processed2mo ago SEC9999999995-26-002761
Actionable Insight ▼ Bearish

The effectiveness of this massive resale shelf creates immediate and severe overhang. Selling stockholders can now sell into the market at any time, and with the company in a strategic-alternatives process with no active pipeline, the stock faces persistent downward pressure. Traders should expect continued weakness and potential large-block sales. Any strategic alternative announcement (sale, merger, or liquidation) would be the primary catalyst to watch, but the overhang will cap any upside.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$1.14
T+0 close · Aug 26, 2026 · via day close
Latest settled
+250.88%
T+20 · $4.00 · next T+60 in 2d
Vs SPY
+250.65%
α at T+20
Latest observation
+381.10%
T+41 · FF3 residual α
  1. T+0 · Aug 26 $1.14entry
  2. T+1 · 3mo ago +1.75%α +1.10% · $1.16
  3. T+5 · 3mo ago +2.63%α +2.75% · $1.17
  4. T+20 · 8w ago +250.88%α +250.65% · $4.00
  5. T+57 · todayOpen
  6. T+60 · in 2d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The SEC declared effective Indaptus Therapeutics' S-3 registration (File No. 333-298388) on August 25, 2026, covering up to 58,895,000 shares of common stock for resale by selling stockholders. This effectiveness, combined with a prior S-3 from June 2026 covering 18,864,000 shares, creates a massive potential overhang of up to ~77.8 million shares (~58% of outstanding) that selling stockholders can now sell into the market at any time. The company has no active clinical programs, having discontinued its lead candidate Decoy20, and is evaluating strategic alternatives, making this a significant bearish catalyst for the stock.

Key Facts

  • S-3 registration (File No. 333-298388) declared effective on August 25, 2026.
  • Registration covers up to 58,895,000 shares of common stock for resale by selling stockholders.
  • Combined with a prior June 2026 S-3 covering 18,864,000 shares, total potential overhang is ~77.8 million shares (~58% of outstanding).
  • Company has discontinued all clinical development of its lead candidate Decoy20 and has no active programs.
  • Auditor has expressed substantial doubt about the company's ability to continue as a going concern.
  • Company is evaluating strategic alternatives.

Financial Impact

Potential dilution overhang of up to ~77.8 million shares (~58% of outstanding) from two S-3 resale registrations now effective. No new capital raised for the company.

dilutionmarket overhang

Risk Factors

  • Immediate selling pressure from stockholders who can now resell up to 58.9M shares into the market.
  • Combined overhang of ~77.8M shares (~58% of outstanding) from two effective S-3 resale registrations.
  • No active clinical programs or revenue to support valuation.
  • Going concern risk with substantial doubt from auditor.
  • Potential for further dilutive financing if strategic alternatives fail to materialize.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (INDP), Batch item 19999999995-26-002761
Document: 9999999995-26-002761-index.html9999999995-26-002761
Document: 9999999995-26-002761.txt9999999995-26-002761
EFFECT Filing (INDP), Batch item 49999999995-26-002761
Document: 9999999995-26-002761-index.html9999999995-26-002761
Document: 9999999995-26-002761.txt9999999995-26-002761

Track record

20 reports on INDP

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +59.35% at T+20 after the Jul 20, 2026 report. 6 of 9 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.17 Now $3.45 +8.83% settles Dec 15
  2. Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  3. Oct 22, 202625d ago SC 13D/A Neutral 3/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  4. Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  5. Oct 21, 202626d ago SC 13D/A Neutral 4/10 Entry $2.99 Now $3.45 +15.38% settles Nov 19
  6. Oct 20, 202627d ago 8-K Bearish 6/10 Entry $3.16 Now $3.45 −9.18% settles Nov 18
  7. Sep 30, 20266w ago 8-K Neutral 3/10 Entry $2.30 to $3.31 Now $3.45 +50.00% ▲ +43.70% +42.43% vs SPY
  8. Sep 9, 20269w ago 8-K Bearish 7/10 Entry $2.56 to $2.37 Now $3.45 −34.77% ▲ +7.42% +9.55% vs SPY
  9. Sep 4, 202610w ago 424B5 Bearish 6/10 Entry $1.85 to $2.59 Now $3.45 −86.49% ▼ −40.00% −38.29% vs SPY
  10. Sep 1, 202610w ago 8-K Bearish 5/10 Entry $1.13 to $2.32 Now $3.45 −205.31% ▼ −104.87% −103.69% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 26, 2026